---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-105914"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:35:14.092873+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q3 net loss $69.4M; SOL-R hits 555 subjects; cash ~$790M with offering

## Summary
- Net loss $(69.4)M ($0.38 loss per share) vs $(36.5)M loss in Q3 2024; revenue $14.5M, down 5.8% YoY.
- SOL-R registrational trial in wet AMD achieved target randomization of 555 subjects; topline data on track for 1H 2027.
- Cash balance $344.8M at Sep 30, plus ~$445M net proceeds from Oct equity offering providing runway into 2028.
- HELIOS Phase 3 program for AXPAXLI in NPDR to start imminently using novel DRSS endpoint.
- R&D expenses rose to $52.4M from $37.1M due to clinical trial costs.

## SEC filing metadata
- accession: 0001104659-25-105914
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/0001104659-25-105914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/tm2530039d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-105914
- JSON: https://secwatch.observer/filing/0001104659-25-105914.json
- Plain text: https://secwatch.observer/filing/0001104659-25-105914.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.